Secondary Logo

Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis

An Autopsy-Confirmed Case

Tago, Tetsuro, PhD*; Toyohara, Jun, PhD*; Sengoku, Renpei, MD, PhD†‡; Murayama, Shigeo, MD, PhD†‡; Ishii, Kenji, MD*

doi: 10.1097/RLU.0000000000002564
Interesting Images
Open

An 86-year-old woman with cognitive impairment and left hemiparesis underwent 18F-THK5351 PET 4 months before her death. In addition to “normal” off-target binding in the basal ganglia, abnormal accumulation was observed along the pyramidal tract and around the right basal ganglia as ring-shaped uptake that overlapped a gadolinium-enhanced lesion. Postmortem pathological examination revealed that she had glioblastoma multiforme with associated gliosis, in which monoamine oxidase B (MAO-B) activity is increased. In vitro autoradiography of the corresponding lesion demonstrated specific binding of 18F-THK5351, which was blocked by an MAO-B–selective ligand. Thus, 18F-THK5351 PET may reflect glioblastomas and associated gliosis by binding to MAO-B.

From the *Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology; and

Departments of Neurology and

Neuropathology, Brain Bank for Aging Research, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.

Received for publication December 18, 2018; revision accepted January 25, 2019.

Conflicts of interest and sources of funding: This study was supported by a research grant from Novartis Pharma and JSPS KAKENHI grants JP16H06277, JP17K09813, and JP18K15655. None declared to all authors.

CME/CE disclosure: 18F-THK5351 can be used for research purposes.

Correspondence to: Jun Toyohara, PhD, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2, Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan. E-mail: toyohara@pet.tmig.or.jp.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors thank Dr Nobuyuki Okamura (Tohoku Medical and Pharmaceutical University, Sendai, Japan) and Tohoku University, Sendai, Japan, for kindly providing the precursor and reference material for the synthesis of 18F-THK5351, the members of the Research Team for Neuroimaging and Research Team for Geriatric Pathology at the Tokyo Metropolitan Institute of Gerontology for their technical assistance, and Comprehensive Research Brain Science Network from Ministry of Education, Culture, Sports, Science and Technology, Japan, for preparation of brain samples.

Back to Top | Article Outline

REFERENCES

1. Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.
    2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820.
      3. Ishibashi K, Kameyama M, Tago T, et al. Potential use of 18F-THK5351 PET to identify wallerian degeneration of the pyramidal tract caused by cerebral infarction. Clin Nucl Med. 2017;42:e523–e524.
        4. Harada R, Ishiki A, Kai H, et al. Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med. 2018;59:671–674.
          5. Cesura AM, Imhof R, Takacs B, et al. [3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes. J Neurochem. 1988;50:1037–1043.
            6. Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–214.
              7. Tago T, Furumoto S, Okamura N, et al. Structure-activity relationship of 2-arylquinolines as PET imaging tracers for tau pathology in Alzheimer disease. J Nucl Med. 2016;57:608–614.
                8. Gabilondo AM, Hostalot C, Garibi JM, et al. Monoamine oxidase B activity is increased in human gliomas. Neurochem Int. 2008;52:230–234.
                  9. Fowler JS, Logan J, Volkow ND, et al. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol. 2005;7:377–387.
                    Keywords:

                    18F-THK5351; glioblastoma; monoamine oxidase B; PET

                    Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.